Landspítali Awards ISK 13.8 Billion Pharmaceutical Framework in Iceland Materials and Products

Standfirst:

Landspítali Háskólasjúkrahús has concluded a major pharmaceutical procurement covering various medicines under the “Ýmis lyf 80 Æxlishemjandi lyf” programme in Iceland. The procurement has a maximum framework value of ISK 13.8 billion and an estimated duration of two years. Multiple pharmaceutical suppliers were selected for contracts covering medicines supplied through companies including Icepharma, Vistor, Alvogen ehf and Williams & Halls ehf. The procurement uses an open procedure and is classified under CPV 33600000 for pharmaceutical products.

Introduction

Landspítali Háskólasjúkrahús has completed a significant pharmaceutical procurement programme covering medicines required by Iceland's university hospital. The TED result notice identifies the procurement as “Ýmis lyf 80 Æxlishemjandi lyf” and classifies the contract as a supplies procurement for pharmaceutical products. The procurement is particularly important because the framework is designed to provide access to a broad range of medicines through multiple supplier arrangements rather than relying on a single pharmaceutical provider.

The maximum value of the framework agreement is stated as ISK 13,800,000,000. The framework has an estimated duration of two years and applies to the Höfuðborgarsvæði region of Iceland. The procurement was conducted through an open procedure and was not accelerated. The legal basis stated in the notice is Directive 2014/24/EU.

The result notice records contracts concluded on 16 January 2026. The supplier information shows a wide distribution of awards across pharmaceutical companies and commercial representatives, reflecting the breadth of products covered by the procurement.

Why This Contract Matters

The procurement matters because pharmaceutical supply is a core component of hospital operations and continuity of healthcare delivery. A large framework covering medicines allows a major healthcare institution to establish structured procurement arrangements with several suppliers and product representatives. This can support continuity of supply while giving the buyer access to different manufacturers and pharmaceutical portfolios.

The ISK 13.8 billion maximum framework value indicates the strategic scale of the procurement. However, the maximum framework value should not be interpreted as confirmed revenue for any individual supplier because the notice does not allocate that entire amount to one company. Instead, the framework establishes the maximum value available across the procurement arrangement.

The multi supplier structure is also important from a procurement risk perspective. Pharmaceutical procurement can be exposed to availability constraints, manufacturer changes, product substitution requirements and supply continuity challenges. Maintaining several awarded suppliers can provide the buyer with greater flexibility when sourcing medicines over the framework period.

Contract Timeline

The procurement was conducted as an open procedure and was not accelerated. The TED notice identifies the internal procurement identifier as 35034. The contracts recorded in the result notice show winner selection and contract conclusion dates of 16 January 2026.

The framework has an estimated duration of two years. The result notice was published in OJ S 178/2026 on 15 September 2026 under notice number 633838 2026.

Contract Overview

The procurement covers pharmaceutical products required by Landspítali Háskólasjúkrahús. The title “Ýmis lyf 80 Æxlishemjandi lyf” identifies the procurement as part of the hospital's broader pharmaceutical purchasing activity and specifically relates to medicines within the programme identified in the notice.

The main CPV classification is 33600000, Pharmaceutical products. The place of performance is Iceland, within the Höfuðborgarsvæði NUTS region IS001. The procurement is structured as a framework agreement with a maximum value of ISK 13.8 billion and a duration of two years.

Key Contract Details

Project Scope

The procurement is intended to secure pharmaceutical products for Landspítali Háskólasjúkrahús under the Ýmis lyf 80 programme. The main classification, CPV 33600000, confirms that the procurement is centred on pharmaceutical products. The notice indicates that detailed information is contained in the tender documents available electronically through the Mercell Tendsign procurement portal.

The procurement is not presented as a single product purchase. Instead, the result notice records multiple contracts with different suppliers and supplier representatives. Tender identifiers refer to manufacturers and pharmaceutical portfolios including Bayer, Merck, Daiichi Sankyo, Gilead, Roche, Servier, Pfizer, Amgen, Eisai, Novartis, GSK, MSD and other pharmaceutical businesses represented through the successful suppliers.

This structure allows the hospital to source medicines from different pharmaceutical channels within the same procurement programme. It also illustrates the role of local pharmaceutical distributors and representatives in connecting international manufacturers with Iceland's institutional healthcare market.

About the Contracting Authority

Landspítali Háskólasjúkrahús is identified as the buyer and the organisation signing the contracts in the TED notice. The hospital is Iceland's university hospital and is responsible for a substantial range of specialist healthcare activities.

The procurement demonstrates the scale of pharmaceutical purchasing required to support a major hospital environment. By using a structured framework with multiple suppliers, the buyer can establish procurement arrangements covering a broad pharmaceutical requirement over a defined two year period.

About the Organisations Involved

Landspítali Háskólasjúkrahús is the buyer and the organisation signing the contracts. It is responsible for the procurement and the resulting pharmaceutical supply arrangements. The procurement reference shown in the notice is 35034.

Icepharma is identified repeatedly as a successful supplier. The notice records Icepharma contracts associated with pharmaceutical portfolios from companies including Merck, Bayer, Daiichi Sankyo, Krka, Roche, Servier and Gilead.

Vistor is another major successful supplier identified throughout the result notice. Its contracts include tender identifiers connected with manufacturers and pharmaceutical businesses such as Astellas, Eisai, Pierre Fabre, Novartis, GSK, Amgen and MSD.

Alvogen ehf is also recorded as a successful supplier. The notice identifies an Alvogen ehf tender and a corresponding contract concluded on 16 January 2026.

Williams & Halls ehf is another awarded supplier. The result notice records the company as the winner associated with the tender identifier “ÝMIS LYF 80 W&H” and contract number 21.

The tender information also references major pharmaceutical manufacturers through supplier tender identifiers. These include Pfizer, Bayer, Merck, Daiichi Sankyo, Gilead, Roche, Servier, Amgen, Eisai, Novartis, GSK, MSD, Krka and Pierre Fabre. The notice generally presents these names within tender identifiers and supplier representation arrangements rather than as separate contracting parties.

Procurement Analysis

The procurement is notable for its framework structure and high maximum value. At ISK 13.8 billion, the framework provides substantial purchasing capacity over two years. Because multiple suppliers were selected, the arrangement appears designed to accommodate a wide pharmaceutical portfolio rather than concentrate supply through one organisation.

The open procedure provides a transparent competitive route for eligible pharmaceutical suppliers. The absence of an accelerated procedure indicates that the procurement followed a standard process rather than an emergency procurement route.

The result data also highlights an important characteristic of pharmaceutical procurement reporting. Individual tender values are recorded as ISK 0.00 in the result notice for the contracts shown in the file. These zero values should not be interpreted as evidence that pharmaceutical products were supplied without payment. Rather, the published tender result does not provide a monetary value for those individual awards.

Additional Procurement Facts

The procurement is not financed with EU funds and is not covered by the Government Procurement Agreement. The framework has a maximum value of ISK 13.8 billion and an estimated duration of two years.

The procurement uses CPV 33600000 for pharmaceutical products and is geographically associated with Höfuðborgarsvæði in Iceland. The notice states that additional tender information is available through the Mercell Tendsign procurement portal.

Market & Industry Perspective

The Landspítali procurement provides an important indicator of demand in Iceland's institutional pharmaceutical market. A framework of this scale creates a structured purchasing channel for suppliers capable of meeting hospital pharmaceutical requirements over multiple years.

The participation of several local suppliers representing international pharmaceutical manufacturers illustrates the importance of distribution networks in smaller national markets. International manufacturers may rely on established local commercial partners to manage market access, distribution and institutional procurement requirements.

The supplier landscape also indicates that competition is not limited to manufacturers themselves. Pharmaceutical distributors and local representatives can play an important role in securing institutional contracts by combining product access with local regulatory, logistics and supply capabilities.

Economic Significance

The ISK 13.8 billion maximum framework value represents a substantial procurement opportunity within Iceland's healthcare supply chain. Although the maximum value does not represent confirmed expenditure or guaranteed supplier revenue, it indicates the potential scale of pharmaceutical purchasing capacity available through the framework.

The procurement can support pharmaceutical distributors, manufacturers and related logistics businesses operating within Iceland's healthcare ecosystem. A reliable pharmaceutical supply chain is also essential for maintaining continuity of hospital services and ensuring that medicines can be made available when required.

Future Procurement Opportunities

The two year framework creates a clear procurement cycle for suppliers monitoring Icelandic pharmaceutical opportunities. Businesses that were successful in this procurement can use the resulting contract relationships as a basis for participating in future pharmaceutical requirements, while other suppliers can study the procurement structure and prepare for subsequent competitions.

Future procurement opportunities may continue to cover medicines through specialised pharmaceutical categories and manufacturer portfolios. Suppliers should monitor Landspítali procurement activity and broader Icelandic healthcare purchasing programmes for similar requirements.

CPV 33600000 should be an important monitoring code for companies seeking comparable opportunities. Suppliers can combine CPV based searches with manufacturer names, medicine categories and Icelandic healthcare buyer information to identify relevant tenders earlier in the procurement cycle.

Opportunities for Suppliers

The procurement creates opportunities for both pharmaceutical manufacturers and distributors. The repeated appearance of local suppliers representing international manufacturers shows that companies do not necessarily need to manufacture medicines themselves to participate in institutional pharmaceutical procurement.

Suppliers can strengthen their position by developing reliable distribution capabilities, maintaining access to pharmaceutical portfolios and understanding the procurement requirements of Icelandic healthcare institutions. The ability to represent multiple manufacturers can also provide a broader opportunity set within pharmaceutical framework competitions.

What Businesses Should Watch

Pharmaceutical companies should monitor the renewal and replacement cycle associated with the two year framework. Upcoming requirements can provide opportunities for suppliers that were not selected in the current procurement or for manufacturers entering the Icelandic market with relevant pharmaceutical products.

Businesses should also watch changes in medicine demand, supplier arrangements and product portfolios. The tender identifiers in the result notice demonstrate that several international pharmaceutical manufacturers are represented through local suppliers.

Procurement teams should pay attention to the distinction between framework capacity and actual awarded expenditure. The ISK 13.8 billion figure represents the maximum framework value and should not be reported as a confirmed payment to any individual supplier.

TendersOnTime.com Procurement Intelligence

From a procurement intelligence perspective, this Icelandic pharmaceutical framework demonstrates the value of tracking procurement at three interconnected levels: buyer, supplier and manufacturer. A search focused only on the buyer could identify the Landspítali opportunity, while supplier and manufacturer intelligence reveals the commercial structure behind the individual awards.

The procurement also demonstrates why framework maximum values should be analysed carefully. ISK 13.8 billion represents the purchasing ceiling stated in the notice, not confirmed revenue. The individual tender records in the result notice show ISK 0.00, meaning that the published result does not provide a reliable monetary allocation to each supplier. Procurement intelligence should therefore distinguish between maximum framework capacity, individual tender values and actual expenditure data.

For suppliers, the strongest lesson is the importance of local market positioning. Vistor, Icepharma, Alvogen ehf and Williams & Halls ehf appear as successful supplier organisations, while tender identifiers connect them with multiple international pharmaceutical manufacturers. This suggests that local representation, distribution capability and established institutional relationships can be important competitive assets in a market such as Iceland.

The framework also indicates that future pharmaceutical procurement could remain highly portfolio driven. Rather than treating the market as one broad pharmaceutical opportunity, suppliers should identify individual medicine categories, manufacturer relationships and CPV classifications. This approach can help businesses identify smaller but highly relevant opportunities within large healthcare procurement programmes.

For businesses using TendersOnTime.com, the strategic opportunity is to combine CPV monitoring with buyer intelligence and supplier tracking. CPV 33600000 can identify pharmaceutical procurement activity, while historical award data can show which distributors and pharmaceutical representatives have previously won contracts. This creates a more targeted approach to market entry, competitor analysis and future tender preparation.

Supplier Takeaways

• Monitor Landspítali Háskólasjúkrahús for future pharmaceutical procurement opportunities.
• Track CPV 33600000 for pharmaceutical product tenders.
• Use Icelandic healthcare procurement activity as an indicator of institutional pharmaceutical demand.
• Monitor the two year framework cycle for future renewal opportunities.
• Local distribution and representation can be important for international pharmaceutical manufacturers entering Icelandic institutional markets.
• Track suppliers such as Icepharma, Vistor, Alvogen ehf and Williams & Halls ehf for competitive intelligence.
• Monitor manufacturer relationships appearing in tender identifiers.
• Maintain reliable pharmaceutical logistics and supply capabilities.
• Do not interpret the ISK 13.8 billion maximum framework value as guaranteed supplier revenue.
• Do not interpret ISK 0.00 individual tender values as free pharmaceutical supply.
• Combine CPV monitoring with buyer, supplier and manufacturer intelligence.

Key Takeaways

• Landspítali Háskólasjúkrahús is the buyer for the Icelandic pharmaceutical procurement.
• The procurement title is “Ýmis lyf 80 Æxlishemjandi lyf”.
• The maximum framework value is ISK 13.8 billion.
• The framework has an estimated duration of two years.
• The procurement concerns pharmaceutical products.
• The main CPV code is 33600000.
• The procurement uses an open procedure.
• The procedure was not accelerated.
• The legal basis is Directive 2014/24/EU.
• The procurement is associated with Höfuðborgarsvæði, Iceland.
• Contracts recorded in the notice were concluded on 16 January 2026.
• Icepharma is recorded as a successful supplier across multiple pharmaceutical portfolios.
• Vistor is recorded as a successful supplier across multiple pharmaceutical portfolios.
• Alvogen ehf and Williams & Halls ehf are also recorded as successful suppliers.
• The notice states that the procurement was not financed with EU funds.
• The procurement is not covered by the GPA.
• Individual tender values are recorded as ISK 0.00 in the published result data and should not be interpreted as confirmed contract expenditure.

Conclusion

Landspítali's ISK 13.8 billion pharmaceutical framework represents a major institutional procurement opportunity in Iceland and establishes a two year structure for sourcing pharmaceutical products through multiple suppliers. The award distribution across Icepharma, Vistor, Alvogen ehf and Williams & Halls ehf highlights the importance of local pharmaceutical distribution and manufacturer representation.

For suppliers, the procurement provides a valuable benchmark for understanding Iceland's institutional pharmaceutical market. Monitoring CPV 33600000, Landspítali procurement activity, supplier relationships and international manufacturer representation can help businesses identify future opportunities and develop stronger procurement strategies.

Source: Official Journal of the European Union, TED Contract or Concession Award Notice 633838 2026, OJ S 178/2026, published 15 September 2026.